Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Conditions:   Metastatic Colorectal Cancer;   Metastatic Pancreatic Cancer;   Metastatic Ovarian Cancer;   Metastatic Breast Carcinoma;   Neuroendocrine Tumors;   Metastatic Endocrine Tumors
Interventions:   Biological: Young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Pembrolizumab (Keytruda)
Sponsor:   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments